Elusys Therapeutics has received a five-year contract worth up to $143 million from the HHS to bolster human trials and production of Anthim, a protein-based drug for inhaled anthrax. The treatment is expected to compete with Human Genome Sciences' raxibacumab, which is also designed to treat inhaled anthrax.

Related Summaries